Literature DB >> 23248026

[Cardiomyopathies and myocarditis].

F von Knobelsdorff-Brenkenhoff1, J Schulz-Menger.   

Abstract

CLINICAL ISSUE: Cardiomyopathies and myocarditis are frequently challenging in clinical practice regarding differentiation, risk stratification and treatment strategy. There are various disease entities which often affect young or middle-aged adults and the course is variable from asymptomatic and irrelevant for prognosis to sudden cardiac death or severe heart failure even at an early age. Making the right diagnosis is therefore fundamental to correctly identify affected patients and to initiate treatment steps in time. STANDARD TREATMENT: Whereas causal treatment options exist for some forms of cardiomyopathy, the majority of patients receives standard heart failure and device therapy but others require lifelong careful monitoring. DIAGNOSTIC WORK-UP: The diagnosis of cardiomyopathy is mainly based on the cardiac phenotype; therefore, non-invasive imaging is very important. Cardiovascular magnetic resonance has become the gold standard to assess cardiomyopathy as it combines functional information (e.g. wall motion) with myocardial tissue analysis (e.g. fibrosis and edema) and in some cases it can replace invasive endomyocardial biopsies. PERFORMANCE: The importance of cardiovascular magnetic resonance to assess cardiomyopathy is based on several aspects: accurate analysis of cardiac dimensions and function, non-invasive tissue analysis to make the diagnosis (e.g. myocarditis), estimation of prognosis by non-invasive tissue analysis, high reproducibility for accurate follow-up examinations, potential for technical improvements (e.g. quantification of extracellular volume fraction by T1 mapping). ACHIEVEMENTS: In all types of cardiomyopathy, cardiovascular magnetic resonance has a major impact on the differential diagnosis, risk stratification and treatment. In some entities the appropriate clinical use is already confirmed by evidence (e.g. myocarditis) and in others there are first encouraging results that indicate the future potential (e.g. risk stratification in hypertrophic cardiomyopathy). PRACTICAL RECOMMENDATIONS: Cardiovascular magnetic resonance has evolved as the gold standard to assess cardiomyopathy as it provides both functional and morphological information. It is recommended to use this technique in a comprehensive approach to achieve complete work-up of affected patients.

Entities:  

Mesh:

Year:  2013        PMID: 23248026     DOI: 10.1007/s00117-012-2380-6

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  22 in total

1.  Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients from the EuroCMR Registry.

Authors:  Oliver Bruder; Steffen Schneider; Detlev Nothnagel; Günter Pilz; Massimo Lombardi; Anil Sinha; Anja Wagner; Thorsten Dill; Herbert Frank; Albert van Rossum; Jürg Schwitter; Eike Nagel; Jochen Senges; Georg Sabin; Udo Sechtem; Heiko Mahrholdt
Journal:  JACC Cardiovasc Imaging       Date:  2011-11

2.  2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association.

Authors:  Kenneth Dickstein; Panos E Vardas; Angelo Auricchio; Jean-Claude Daubert; Cecilia Linde; John McMurray; Piotr Ponikowski; Silvia Giuliana Priori; Richard Sutton; Dirk J van Veldhuisen
Journal:  Eur Heart J       Date:  2010-08-27       Impact factor: 29.983

3.  Cardiac MR imaging of nonischemic cardiomyopathies: imaging protocols and spectra of appearances.

Authors:  David H O'Donnell; Suhny Abbara; Vithaya Chaithiraphan; Kibar Yared; Ronan P Killeen; Ramon Martos; David Keane; Ricardo C Cury; Jonathan D Dodd
Journal:  Radiology       Date:  2012-02       Impact factor: 11.105

4.  The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology.

Authors:  Leslie T Cooper; Kenneth L Baughman; Arthur M Feldman; Andrea Frustaci; Mariell Jessup; Uwe Kuhl; Glenn N Levine; Jagat Narula; Randall C Starling; Jeffrey Towbin; Renu Virmani
Journal:  Eur Heart J       Date:  2007-10-24       Impact factor: 29.983

5.  The 2006 American Heart Association classification of cardiomyopathies is not the gold standard.

Authors:  Perry Elliott
Journal:  Circ Heart Fail       Date:  2008-05       Impact factor: 8.790

6.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.

Authors:  Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

7.  Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease.

Authors:  Daniel M Sado; Andrew S Flett; Sanjay M Banypersad; Steven K White; Viviana Maestrini; Giovanni Quarta; Robin H Lachmann; Elaine Murphy; Atul Mehta; Derralynn A Hughes; William J McKenna; Andrew M Taylor; Derek J Hausenloy; Philip N Hawkins; Perry M Elliott; James C Moon
Journal:  Heart       Date:  2012-08-30       Impact factor: 5.994

8.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Perry Elliott; Bert Andersson; Eloisa Arbustini; Zofia Bilinska; Franco Cecchi; Philippe Charron; Olivier Dubourg; Uwe Kühl; Bernhard Maisch; William J McKenna; Lorenzo Monserrat; Sabine Pankuweit; Claudio Rapezzi; Petar Seferovic; Luigi Tavazzi; Andre Keren
Journal:  Eur Heart J       Date:  2007-10-04       Impact factor: 29.983

9.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

Authors:  James C C Moon; Bhavesh Sachdev; Andrew G Elkington; William J McKenna; Atul Mehta; Dudley J Pennell; Philip J Leed; Perry M Elliott
Journal:  Eur Heart J       Date:  2003-12       Impact factor: 29.983

10.  Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis.

Authors:  Alicia M Maceira; Sanjay K Prasad; Philip N Hawkins; Michael Roughton; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2008-11-25       Impact factor: 5.364

View more
  1 in total

1.  Effects of tanshinone IIA on the transforming growth factor β1/Smad signaling pathway in rat cardiac fibroblasts.

Authors:  Cheng-Ye Zhan; Jin-Hui Tang; Dai-Xing Zhou; Zhi-Hui Li
Journal:  Indian J Pharmacol       Date:  2014 Nov-Dec       Impact factor: 1.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.